Biohaven Pharmaceutical files for IPO


NEW HAVEN, Conn. — Biohaven Pharmaceutical filed a Form S-1 with the Securities and Exchange Commission, hoping to obtain up to $100 million in proceeds from its initial public offering. The company plans to list its shares under the ticker symbol BHVN on the New York Stock Exchange.

New Haven-based Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. The company’s first drug candidate, BHV-0223, is a novel formulation of a glutamate-modulating agent, being developed under FDA 505(b)(2) guidelines for Amyotrophic Lateral Sclerosis (or Lou Gehrig’s disease). The FDA cleared the Company’s IND for BHV-0223 in August 2015, and Biohaven has completed a pharmacokinetic study in humans and is planning to launch a pivotal bioequivalence study.

Biohaven’s second clinical compound, trigriluzole, is a New Molecular Entity for neurodegenerative diseases, neuropsychiatric disorders and potentially cancer indications. The company states it plans to advance other approaches and is actively exploring licenses for additional compounds.

This ad will auto-close in 10 seconds